This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Informa Connect's Hub and Specialty Pharmacy Models West. September 14-15, 2022 Sheraton San Diego Hotel & Marina | San Diego, CA www.informaconnect.com/hub-specialty-pharmacy-west. Offer not valid on workshop only or academic/non-profit registrations. Delivered as a Hybrid Event. Drug Channels, or any of its employees.
Informa Connect’s Hub and Specialty Pharmacy Models East. June 28-30, 2022 | Sheraton Parsippany | Parsippany, NJ www.informaconnect.com/hub-specialty-pharmacy. For 2022 only, Hub and Specialty Pharmacy Models and PAP – Patient Assistance & Access Programs are under the same roof. Delivered as a Hybrid Event.
This important event convenes key stakeholders including manufacturers, specialty pharmacies, hubs, payers, PBMs, physicians and more to explore strategies for developing and integrating hub programs and other patient-centric services to ensure product access and optimal reimbursement. Arquette, R.Ph.,
Informa Connect’s Access USA March 19-21, 2024 | Pre-Conference Workshops on March 18, 2024 Philadelphia Marriott Downtown in Philadelphia, PA Exclusive Offer – Be sure to use your exclusive promocode 24AUSA10 to save 10% off* of your registration. What is Access USA?
Choose between 3 Interactive Workshops on Day 2! Drug Channels readers are eligible for an exclusive savings of 10% off * the current rate by using promo code 21FRADC10 , be sure to reserve your seat today!
However, the agency can describe a concomitant therapy in labeling for a product it has authority to regulate if it is essential for the therapeutic effect. While the ability to describe and specify aspects of the therapy is limited, the agency can specify the number and licensure of therapists who would participate in the MDMA treatment.
This alliance with Bristol Myers Squibb is a natural area of collaboration for FAMU, given our College of Pharmacy and Pharmaceutical Sciences, Institute of Public Health,” said Larry Robinson, Ph.D. and the Doctor of Physical Therapy. President of Florida A&M University. “We The three professional degrees include the J.D.,
Based on the results of its evaluation of nominated categories of drug products to date, as well as consultation with the Pharmacy Compounding Advisory Committee (PCAC), FDA is also proposing to include certain categories of drug products on these lists. The rule, will also, if finalized, address communication with State boards of pharmacy.
Title Type Comments Close Fixed-Combinations and Single-Entity Versions of Previously Approved Antiretrovirals for the Treatment or Prevention of Human Immunodeficiency Virus-One Under the President’s Emergency Plan for Acquired Immunodeficiency Syndrome Relief Guidance November 1 Post-Warning Letter Meetings Under GDUFA Guidance November 6 In-Home (..)
” Interchangeable products can be substituted for the reference product at the pharmacy level, without prescriber intervention, within state and local regulations. In September 2022, the FDA held a workshop focused on increasing the efficiency of biosimilar development programs.
The side effects of some anticancer treatments can result in dose interruptions or de-escalations, or even outright discontinuation of an efficacious therapy. In 2015, the FDA, along with the American Association for Cancer Research (AACR), held a workshop on dose optimization for small molecules.
Title Type Date Cleared by OIRA Legal Deadline None Notable FDA Comment Periods Closing in December and January FDA comment periods are typically open for 30-60 days, unless they are extended.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content